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When 21 biopharmaceutical companies recent-ly launched the Access Accelerated Initiative (AAI) on prevention and care for non-com-
municable diseases (NCD) [1] in Davos, Switzerland, it 
was described as a ‘global, multi-stakeholder collabora-
tion’. The need for partnership is included in the Sus-
tainable Development Goals (SDG). SDG 17 aims to “Revitalize the global partnership for sustainable 
development” and requires inclusive partnerships between governments, civil society and the private 
sector [2].
The launch of the AAI leaves many questions unanswered regarding exactly how this partnership mod-
el is organized. From the little information publicly available, AAI presents a skewed view of what part-
nerships in global health should be. The International Federation of Pharmaceutical Manufacturers and 
Associations (IFPMA) acts as its Secretariat and no government or multi-lateral agency, besides the 
World Bank, is included. The Union for International Cancer Control (UICC) represents civil society. 
The AAI states that other NCD organizations will be involved, but these organizations are dwarfed by 
pharmaceutical company partners and most, including the UICC, are reliant on funding from these 
same companies [3].
Partnerships with pharmaceutical compa-
nies have shown some success, as seen with 
HIV/AIDS, vaccines and Neglected Tropical 
Diseases (NTD) [4-7]. In these partnerships 
each stakeholder had a specific role. Fund-
ing came from bi-lateral and multi-lateral 
donors, civil society played the role of ad-
vocate and implementer, and the pharma-
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Partnerships with pharmaceutical companies 
have shown some success for example with HIV/
AIDS, vaccines and neglected tropical diseases.
Responsibilities in addressing access to NCD 
medicines lie with the World Health Organiza-
tion, governments, donors, and civil society 
with the role of the private sector to comple-







ceutical industry either developed new products or made exist-
ing medicines available for free or at differential prices with 
long-term pledges.
Responsibilities in addressing access to NCD medicines lie with 
the World Health Organization (WHO), governments, donors, 
and civil society. The role of the private sector is to complement 
these roles; not to replace them. Transparency in company ini-
tiatives is often lacking. It is therefore welcome news that AAI 
will be evaluated by the Boston University School of Public Health. However, this model of partnership 
raises the following questions:
1.  What is the exact agenda in terms of diseases, approaches and countries, with stated objectives, base-
line data and targets? How has this agenda been set and who has been involved?
2.  Have the intended beneficiaries (patients, governments) been consulted and are locally available struc-
tures (such as national treatment guidelines) respected and supported? In general, are the WHO Guide-
lines for Drug Donations followed? Which partners are responsible for the various components of the 
program?
3. How will the AAI interact with a variety of other stakeholders, nationally and globally?
4. How will long-term sustainability be achieved?
5. How will accountability to the beneficiaries (patients, governments) be ensured?
NCDs are an unprecedented challenge globally. Universal access to NCD medicines requires long-term 
investment by all stakeholders, including companies. Long-term sustainability through locally available 
structures and resources should be a guiding principle in all phases of such initiatives. The SDGs and 
WHO’s Framework of Engagement with Non-State Actors, see an active role for private sector engage-
ment. However, any partnership with the private sector needs to be framed within strict rules of engage-
ment to avoid any perceived or real conflict of interest [8], and need to publicly address the fundamental 
questions we propose.
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Any partnership with the private sector 
needs to be framed within strict rules of 
engagement to avoid any perceived or 
real conflict of interest.
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